Canada markets closed

Adaptive Biotechnologies Corporation (ADPT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
36.49-2.73 (-6.96%)
At close: 4:00PM EDT
Sign in to post a message.
  • k
    kastenz
    Two presentations Sep-29 on COVID epitopes regarding vaccine development and disease testing. ("IDWeek)
  • k
    kastenz
    Morgan Stanley PT $75 as of mid August. Plenty of upside from 36, with Lyme Disease and immune milestones in months.
  • k
    kastenz
    Got a hunch about this company, hyper bullish. Don't want to jinx it with a prediction.
  • R
    RV
    Nice- anybody wants to check it out:

    The thread is very heartening if you have a position in ADPT:

    Simon Barnett@sbarnettARK

    Once Adaptive Biotech launches T-Detect Lyme, and inexorably more autoimmune indications, it may be the only molecular diagnostic company that can add new ‘products’ solely through over-the-air (OTA) software updates.7:35 PM · Aug 19, 2021·Twitter for iPhone
  • T
    Tigat
    ADPT is the best losing stock in my portfolio (thank you Jeff brown and Whitney Tilson).
    All of the ADPT losses in 2021 will mitigate my gains this year.
  • k
    kastenz
    Love this company.
  • R
    RV
    ARK buy:

    ADPT
    September 7, 2021 BUY 192885 0.09% ARKG
  • T
    Tigat
    New to board, but invested on recommendation of a guy named Jeff Brown vouched for by a Whitney tilson. Advice was to buy as long as price was below $50. This effing stock has been in the 30’s for the 3 weeks since I bought.
    I won’t lose money but cashing out next week. If you get advice from brown or tilson, BUYER BEWARE.
  • R
    RV
    Simon Barnett@sbarnettARK

    Replying to @wolfejosh

    Yes, also ending the diagnostic odyssey for Lyme, and potentially dozens of autoimmune diseases with a simple, one-and-done blood test. https://investors.adaptivebiotech.com/news-releases/news-release-details/adaptive-biotechnologies-launches-national-clinical-trial

    Current tests are highly inaccurate, resulting in lengthy diagnostic journey

    An oral medication being developed by a California biopharmaceutical company is in phase-one trials in people. A French biotech company, Valneva, is currently running phase-two clinical trials in the U.S. and Europe for a Lyme disease vaccine. Valneva signed a deal with Pfizer last year to commercialize what it’s calling VLA15.
  • R
    RV
    ARK will add more.
  • k
    kastenz
    RV, I see no studies for 'Vaccibody' AND 'Sars-CoV2' infection at Clinicaltrials.gov.
  • T
    Tom
    Cathy woods.isnt it gambling with these kind of stocks.viac,pfe,wmt,cvx they pay a dividend.how about seed for gambling,they only have a 3.7 million share float.and will be feeding china and india
  • k
    kastenz
    Big ABC down since late June. With all these variants, more money will connect the dots. Morgan Stanley has.
  • M
    Michael
    Hope Cathy Woods has her lipstick ready!
  • R
    RV
    T-Detect anybody!

    This is so crazy- because antibody levels drop after 8 months we need a booster - makes no sense. Antibody levels drop after vaccination or infection as time passes. Basing decisions on serology in 2021 is just not right. Look for specific T cell responses. Delta Variant or any other variant needs to rejig the vacciine but looking at T cell epitopes will help us.
    ADPT needs to TALK.

    Rod Wong, MD@docrodwong·Jul 28

    8 months post 2nd-dose, pfizer phase 1 antibody levels have dropped by over 75%. that doesn't mean protection drops to that degree because we don't have good ways of measuring immune memory. that said, good news a booster dose takes antibody levels ~4x higher than peak.
  • R
    RV
    Another huge buy by ARK:

    August 10, 2021 BUY 268463 0.1058% ARKG
  • M
    Michael
    Plenty of good seats in the front!
  • k
    kastenz
    News this morning on Curebase, Lyme and ADPT:

    "Dr. Lance Baldo, Adaptive's chief medical officer. "The flexibility of Curebase's platform expands our access to hard to reach and more diverse patient groups, while allowing patients to preserve relationships with their providers. The end result is a stronger study and more effective tests that benefit more people."
  • Y
    Yahoo Finance Insights
    Adaptive Biotechnologies is up 6.00% to 32.35
  • k
    kastenz
    What a remarkable company. "T-Detect SARs now, T-Detect Everything later" Lyme on track for this year. Immune to follow. Moderna a customer, and Vaccibody which will use T cell tech, replacing antibody - antibody mechanism could be reason for different strains 'Could result in a universal booster'. Multiple sclerosis, early signal might result in a T-Detect test. Then cancer. Wow, I'm impressed. No secret among brokers, many astute questions on the pipeline, which is growing swiftly.